# Deciphera Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deciphera-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.deciphera.com
- Total disclosed funding: $142M
- Latest round: Series C (Jun 1, 2017)
- Investors on record: 5

## About

Founded in 2003 by founder Daniel L. Flynn and based in Waltham, US, Deciphera Pharmaceuticals, LLC engages in the research, development, and commercialization of medicines and advanced kinase inhibitor treatments for cancer patients, targeting the tumor cell and the tumor microenvironment. In April 2024, Ono Pharmaceutical Co., Ltd. agreed to fully acquire Deciphera Pharmaceuticals, LLC, from Brightstar Associates LLC, BlackRock, Deerfield Management, and Redmile Group for USD 2.4 billion at USD 25.60 per share. The acquisition is expected to be completed in the third quarter of 2024, subject to customary closing conditions.
 
Deciphera's product portfolio primarily consists of kinase inhibitors designed to target specific enzymes involved in cancer cell growth and survival. The company's product, QINLOCK (ripretinib), is approved for the treatment of advanced gastrointestinal stromal tumors (GIST) and is a potent inhibitor of a broad spectrum of KIT and PDGFRa mutations. Another product in Deciphera's pipeline is Vimseltinib, a CSF1R inhibitor for the treatment of tenosynovial giant cell tumour (TGCT). Additionally, Deciphera is developing DCC-3116, a ULK kinase inhibitor, to target autophagy, a process that cancer cells use to survive under stress conditions. The firm's pipeline also includes several other preclinical candidates, such as DCC-3084, a pan-RAF inhibitor in phase 1/2 trials, targeting solid tumors and hematologic malignancies. DCC-3009: A pan-KIT inhibitor in the IND-enabling stage, focusing on GIST. ISR Program: Research-stage development involving a GCN2 activator for the treatment of solid tumors.

## Funding rounds

- Series C, Jun 1, 2017, $52M — New Leaf Venture Partners, Viking Global Investors, Sphera Fund Management, Redmile Group
- Series B, Jan 5, 2016, $15M — SV Health Investors
- Series B, Sep 21, 2015, $75M — New Leaf Venture Partners

## Investors

- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B, Series C
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series C
- Sphera Fund Management — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C